Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥178.80.